CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience

• Published in: Journal of breast cancer Vol. 25; no. 1; pp. 49 - 56
• Main Authors: Jang, Yoon Jung, Jeong, Jae Ho, Kim, Jeong Eun, Ahn, Jin-Hee, Jung, Kyung Hae, Kim, Sung-Bae
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Breast Cancer Society 01.02.2022; 한국유방암학회
• Subjects: Brief Communication; 일반외과학; Lung Diseases, Interstitial; Breast Neoplasms; Genes, erbB-2; Tomography, X-ray Computed; Trastuzumab
• ISSN: 1738-6756; 2092-9900
• DOI: 10.4048/jbc.2022.25.e1

This single-institute, retrospective cohort study enrolled patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab deruxtecan between August 2017 and January 2021 from four previous studies. Of 31 patients, 4 (12.9%) had interstitial lung disease (ILD). The dominant pattern observed on computed tomography was organizing pneumonia (100%), comprising subpleural consolidations in the lung periphery. However, no dominant distribution was observed in radiological lesions of the lungs. Of all the tested patients, lower lobe predominance was noted in 2 (50.0%) patients, upper lobe predominance in 1 (25.0%) patient, and diffused lobe distribution in 1 (25.0%) patient. All events were confined to the Common Terminology Criteria for Adverse Events grade 1 or 2 (100%). None of the patients died. Despite the small number of cases investigated, the incidence of trastuzumab deruxtecan-induced ILD in the Korean population was comparable to that previously reported.